|
Fetal Growth Retardation
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
In conclusion, DES is a potent HSD11B2 inhibitor, possibly contributing to the intrauterine growth restriction.
|
31247589 |
2019 |
|
Fetal Growth Retardation
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Placental 11β-hydroxysteroid dehydrogenase 2 (11β-HSD2), a glucocorticoid-catalyzing enzyme, prevents active glucocorticoids from maternal circulation into the fetus, thus protecting against IUGR.
|
31315888 |
2019 |
|
Fetal Growth Retardation
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
It appears that different causes of IUGR may attenuate HSD11B2 expression differentially in the placenta.
|
30225585 |
2019 |
|
Fetal Growth Retardation
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
It is known that inhibiting 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) expression in the placenta can cause fetal over-exposure to maternal glucocorticoids and induce intrauterine growth restriction (IUGR); these effects ultimately increase the risk of adult chronic diseases.
|
29802914 |
2018 |
|
Fetal Growth Retardation
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Impaired placental 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) activity which inactivates maternal glucocorticoids is associated with poor fetal growth and a higher risk of chronic diseases in adulthood.
|
29486207 |
2018 |
|
Fetal Growth Retardation
|
0.400 |
PosttranslationalModification
|
phenotype |
BEFREE |
In addition, significantly elevated odds of FGR birth were associated with increasing DNA methylation of HSD11B2 and WNT2, and decreasing DNA methylation of IGF2.
|
26678531 |
2016 |
|
Fetal Growth Retardation
|
0.400 |
PosttranslationalModification
|
phenotype |
BEFREE |
These results together show a link between the site-specific methylation of placental HSD11B2 promoter and the development of IUGR.
|
24129435 |
2014 |
|
Fetal Growth Retardation
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
In conclusion, placental 11beta-HSD2 gene expression might predict postnatal growth in IUGR.
|
19218882 |
2009 |
|
Fetal Growth Retardation
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
11beta-HSD1 protein levels were reduced in amnion and 11beta-HSD1 and 11beta-HSD2 oxidase activity in decidua and cotyledon were reduced from pregnancies with IUGR.
|
19776596 |
2009 |
|
Fetal Growth Retardation
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Taken together, our present findings provide evidence suggesting a role for an attenuated placental as well as fetal 11beta-HSD2 in the pathogenesis of IUGR.
|
18061258 |
2008 |
|
Fetal Growth Retardation
|
0.400 |
Biomarker
|
phenotype |
RGD |
Uteroplacental insufficiency alters nephrogenesis and downregulates cyclooxygenase-2 expression in a model of IUGR with adult-onset hypertension.
|
17272666 |
2007 |
|
Fetal Growth Retardation
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
This suggests that the reduced placental 11beta-HSD2 in FGR is not due to intrinsic abnormalities in trophoblast cells, but likely a result of extrinsic factors associated with FGR.
|
16271275 |
2006 |
|
Fetal Growth Retardation
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
No mutations were found in the 11beta-HSD2 gene in the intrauterine growth restriction cohort, and imprinting analysis revealed that the 11beta-HSD2 gene was not imprinted.
|
11600574 |
2001 |
|
Fetal Growth Retardation
|
0.400 |
Biomarker
|
phenotype |
HPO |
|
|
|